## Clinical Diagnosis This patient presents with **systolic heart failure (HFrEF)** with LVEF 35%, characterized by: - Signs of pulmonary congestion (orthopnea, PND, crackles, Kerley B lines) - Signs of systemic congestion (elevated JVP) - Elevated NT-proBNP (>400 pg/mL confirms HF) - No significant valvular disease (primary cardiomyopathy) ## Guideline-Based Management of HFrEF **Key Point:** The foundational pharmacotherapy for HFrEF (LVEF ≤40%) comprises four pillar drugs, initiated in a specific sequence: | Drug Class | Role | Timing | Rationale | |---|---|---|---| | ACE-I / ARB / ARNI | Reduce afterload, prevent remodeling | **First** | Mortality benefit, foundational | | Beta-blocker | Reduce HR, contractility, arrhythmias | **Second** (after ACE-I stabilized) | Mortality benefit, cardioprotective | | MRA (aldosterone antagonist) | Reduce fibrosis, hyperkalemia risk | **Third** (after ACE-I + BB) | Mortality benefit in NYHA II–IV | | SGLT2 inhibitor | Reduce HF hospitalizations, renal protection | **Fourth** (newer evidence) | Class 2a in current guidelines | **High-Yield:** The patient is already euvolemic on diuretics. The next step is to initiate **neurohormonal antagonism** with an ACE inhibitor (lisinopril) and beta-blocker (carvedilol), which are the two most essential agents for mortality reduction in HFrEF [cite:Harrison 21e Ch 297]. ## Why Option 1 (Correct) is Best Lisinopril 2.5 mg daily: - ACE inhibitor; reduces afterload and prevents LV remodeling - Proven mortality benefit in HFrEF (CONSENSUS, SOLVD trials) - Starting dose is low to minimize hypotension risk Carvedilol 3.125 mg twice daily: - Beta-blocker with alpha-blocking properties - Proven mortality reduction in HFrEF (COPERNICUS, CARVICOL trials) - Starting dose is low; titrate up as tolerated Furosemide continuation: - Maintains euvolemia; essential for symptom control **Clinical Pearl:** Always initiate ACE-I *before* beta-blocker in acute decompensation; stabilize on ACE-I, then add beta-blocker. This reduces risk of acute cardiogenic shock from negative inotropy. ## Why Each Distractor is Wrong 1. **Option 0 (Increase amlodipine + furosemide):** Amlodipine is a dihydropyridine calcium-channel blocker with negative inotropic effects; it does NOT reduce mortality in HFrEF and may worsen outcomes. ACE-I and beta-blockers are mandatory first-line agents, not optional. Increasing amlodipine alone delays evidence-based therapy. 2. **Option 2 (Add spironolactone without ACE-I/BB):** Spironolactone is a third-line agent (MRA) used *after* ACE-I and beta-blocker are established. Initiating it first, without neurohormonal blockade, increases hyperkalemia risk and misses the opportunity for early mortality reduction. The sequence matters. 3. **Option 3 (Refer for CRT/ICD):** CRT and ICD are indicated in specific subsets: LVEF ≤35%, QRS ≥120 ms (for CRT), and secondary prevention (prior VT/VF for ICD). The ECG is not provided, and the patient has not yet been optimized on guideline-directed medical therapy (GDMT). CRT/ICD is premature without first establishing ACE-I, beta-blocker, and MRA. ## Management Algorithm ```mermaid flowchart TD A["HFrEF diagnosed<br/>LVEF ≤40%"]:::outcome --> B{"Euvolemic?"}:::decision B -->|No| C["Diuretics, inotropes<br/>as needed"]:::action B -->|Yes| D["Initiate ACE-I<br/>e.g., lisinopril 2.5 mg"]:::action C --> D D --> E["Stabilize on ACE-I<br/>2–4 weeks"]:::action E --> F["Add beta-blocker<br/>e.g., carvedilol 3.125 mg BD"]:::action F --> G["Titrate to target dose"]:::action G --> H["Add MRA if LVEF ≤40%<br/>& NYHA II–IV"]:::action H --> I["Consider SGLT2i"]:::action I --> J{"QRS ≥120 ms?<br/>LVEF ≤35%?"}:::decision J -->|Yes| K["Evaluate for CRT/ICD"]:::action J -->|No| L["Continue GDMT<br/>& follow-up"]:::outcome ``` **Mnemonic:** **ARNI-BB-MRA-SGLT2** = The four-pillar sequence for HFrEF (ACE-I/ARB/ARNI → Beta-Blocker → Mineralocorticoid Receptor Antagonist → SGLT2 inhibitor).
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.